Balsang Pain Relief
Camphor,menthol, Methyl Salicylate
Genuine Drugs
Human Otc Drug
NDC 69666-962Balsang Pain Relief also known as Camphor,menthol, Methyl Salicylate is a human otc drug labeled by 'Genuine Drugs'. National Drug Code (NDC) number for Balsang Pain Relief is 69666-962. This drug is available in dosage form of Solution. The names of the active, medicinal ingredients in Balsang Pain Relief drug includes Camphor, (-)- - 1.5 mg/100mL Menthol, (+)- - 1.5 mg/100mL Methyl Salicylate - 5 mg/100mL . The currest status of Balsang Pain Relief drug is Active.
Drug Information:
| Drug NDC: | 69666-962 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Balsang Pain Relief |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Camphor,menthol, Methyl Salicylate |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Genuine Drugs |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Solution |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | CAMPHOR, (-)- - 1.5 mg/100mL
MENTHOL, (+)- - 1.5 mg/100mL
METHYL SALICYLATE - 5 mg/100mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH NOT FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 20 Apr, 2015 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 16 Jan, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part348 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2024 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| UNII: | |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 69666-962-04 | 1 BOTTLE in 1 BOX (69666-962-04) / 118 mL in 1 BOTTLE | 20 Apr, 2015 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Pain reliever pain reliever pain reliever
Product Elements:
Balsang pain relief camphor,menthol, methyl salicylate water menthol, (+)- menthol methyl salicylate salicylic acid camphor, (-)- camphor (natural) cajuput oil chondroitin sulfate (bovine) cinnamon oil clove oil peppermint oil glucosamine sulfate methylparaben peg-120 methyl glucose dioleate propylparaben diazolidinyl urea
Indications and Usage:
Uses for the temporarily relieves minor aches and pains of muscle and joints associated with arthritis backache stiffness sprains muscle strains
Warnings:
For external use only. when using this product use only as directed avoid contact with eyes and mucous membranes do not apply to wounds, damaged or irritated skin do not bandage or cover with wrap or use heating pad do not use 1 hour prior to bathing or 30 minutes after bathing stop use and ask a doctor if condition worsens severe skin irritation occurs pain persists for more than 7 days pain clears up and then reocurs a few days later. keep out of reach of children if swallowed, get medical help or contact a poison control center immediately if pregnant or breast-feeding ask a health professional before use
When Using:
When using this product use only as directed avoid contact with eyes and mucous membranes do not apply to wounds, damaged or irritated skin do not bandage or cover with wrap or use heating pad do not use 1 hour prior to bathing or 30 minutes after bathing
Dosage and Administration:
Directions shake well before using apply generously to affected areas and massage gently until cream is absorbed into the skin for adults and children over 12, rub well on the affected area. repeat 3-4 times daily for children 12 years of age or younger, consult a doctor before use
Stop Use:
Stop use and ask a doctor if condition worsens severe skin irritation occurs pain persists for more than 7 days pain clears up and then reocurs a few days later.
Package Label Principal Display Panel:
Balsang pain relief carton